RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform
Bennett CF, Swayze EE · Annual Review of Pharmacology and Toxicology, 2010
Bennett CF, Swayze EE
A foundational review of how antisense oligonucleotides work as medicines. It lays out the mechanisms by which an ASO can silence, block or reshape a target RNA, the chemistries that make them stable enough to use, and the pharmacology of the platform. It remains a standard starting point for understanding the ASO field.
Annual Review of Pharmacology and Toxicology, 2010. DOI: 10.1146/annurev.pharmtox.010909.105654
Read the paperRelated in the Knowledge Hub
From theory to a synthesis ready oligo
Syngenis One designs, screens and orders custom oligonucleotides in one guided workflow. Talk to our team or start designing today.
One engine, working across the whole business.
Syngenis One (AI Discovery)
Design RNA and DNA candidates from target to synthesis ready oligo in one workflow.
Manufacturing
Australia's only commercial RNA facility. Custom oligonucleotides, ordered through Syngenis One.
Research and Diagnostics
AI led therapeutic programs and an aptamer based diagnostics pipeline.
Clinical
A specialist nucleic acid CRO with in silico trial modelling.
Life Care
Consumer genomics at a mass market price.
Fund
Infrastructure that channels research investment into the pipeline.